United States Neurology Devices Market Report by Product, End Use, States and Company Analysis, 2026-2034

United States Neurology Devices Market: Future Outlook, Growth Trends & Forecast (2026–2034)

United States Neurology Devices Market is expected to reach US$ 6.74 Billion by 2034 from US$ 3.8 Billion in 2025, with a CAGR of 6.57% from 2026 to 2034. The rising adoption of minimally invasive neuromodulation, neurorehabilitation, brain-computer interfaces, and advanced neurological monitoring technologies is supporting market growth in the United States. Continuous innovation is expanding device applications across stroke, Parkinson’s disease, epilepsy, tremor, pain, and other neurological conditions.

United States Neurology Devices Industry Landscape

Neurology devices are medical technologies designed to diagnose, monitor, manage, or treat disorders affecting the brain, spinal cord, peripheral nerves, and related neurological functions. The category includes neurostimulation systems, deep brain stimulation devices, electroencephalography systems, intraoperative neuromonitoring platforms, brain-computer interfaces, neurorehabilitation technologies, spinal cord stimulators, and specialized diagnostic equipment. Depending on their purpose, these devices can record neural activity, deliver electrical or magnetic stimulation, support functional recovery, or assist physicians during neurological procedures. Advances in digital connectivity, artificial intelligence, wearable technology, and personalized treatment are increasingly improving device capabilities and enabling more targeted, patient-specific approaches to neurological care.

The increasing emphasis on personalized neurological care is creating new opportunities for device manufacturers in the United States. Healthcare providers are seeking technologies capable of delivering more precise stimulation, monitoring neurological changes continuously, and adapting treatment according to individual patient responses. Innovations in wearable neurotechnology, AI-supported diagnostics, brain-computer interfaces, and closed-loop stimulation are expanding the capabilities of conventional neurological devices. At the same time, growing interest in outpatient and home-based treatment is encouraging manufacturers to develop compact, connected, and easier-to-use systems. These developments are broadening device applications across rehabilitation, movement disorders, chronic pain, mental health, epilepsy, and other neurological conditions.

Recent Breakthroughs Shaping the United States Neurology Devices Industry

• In July 2026, Los Angeles-based NeuroSigma began U.S. commercial sales of its second-generation Monarch® eTNS System, a non-drug treatment using trigeminal nerve stimulation for pediatric ADHD. The upgraded device is designed to improve the patient experience while delivering therapeutic stimulation. The launch demonstrates how neurostimulation is expanding beyond traditional pain and movement-disorder applications into pediatric neuropsychiatric care.

Major Growth Drivers Shaping the Future of United States Neurology Devices Sector

1. Personalized Neuromodulation Moves to the Forefront

Neurology device development is increasingly shifting from standardized stimulation toward personalized neuromodulation. Modern systems can incorporate patient-specific physiological information, adaptive settings, digital monitoring, or individualized treatment protocols to improve therapeutic precision. This trend is particularly relevant for movement disorders, chronic pain, depression, tremor, and rehabilitation, where treatment response can vary substantially between patients. Wearable and non-invasive systems are also making personalized stimulation more accessible outside traditional hospital environments. Manufacturers are therefore investing in technologies that combine sensing, software, connectivity, and stimulation within integrated platforms. Such innovations can strengthen clinical decision-making while supporting more convenient treatment pathways. The growing focus on individualized care is consequently creating demand for advanced neurological devices capable of adjusting to changing patient needs.

In April 2026, California-based Cala Health announced FDA clearance for the Cala kIQ Plus, a next-generation wearable neurostimulation device for essential tremor and Parkinson’s disease. The system introduces new therapy modes and adaptive calibration designed to personalize tremor treatment.

2. Neurorehabilitation Technology Expands Beyond Conventional Therapy

Neurological rehabilitation is becoming an important area of device innovation as developers seek technologies that can complement conventional physical and occupational therapy. Electrical stimulation, neuromodulation, robotic assistance, brain-computer interfaces, and digital rehabilitation tools are being investigated to support neuroplasticity and functional recovery following stroke, spinal cord injury, and other neurological conditions. Portable systems can also make therapy more accessible while enabling repeated treatment outside traditional rehabilitation settings. Advances in device design are helping clinicians deliver stimulation more accurately and monitor patient progress. As rehabilitation becomes increasingly technology-enabled, manufacturers are developing systems that combine intuitive interfaces, precise stimulation, and personalized treatment protocols to address diverse recovery requirements.

In April 2026, Neuvotion announced the launch of NeuStim™, an FDA-cleared neuromodulation device designed to provide high-resolution electrical stimulation to muscles for recovery following stroke or spinal cord injury. The company said the system is designed for neurorecovery and physical and occupational therapy applications.

3. Advanced Neuromonitoring Strengthens Surgical Neurology

Neurological and spinal procedures require accurate monitoring of neural structures to help surgical teams identify potential changes during complex operations. This is encouraging hospitals and surgical centers to adopt more advanced intraoperative neuromonitoring technologies. Modern platforms are increasingly designed to simplify setup, improve recording and stimulation capabilities, and integrate multiple monitoring functions within streamlined workflows. Such systems can support monitoring of the brain, spinal cord, and peripheral nerves during procedures where neurological preservation is particularly important. Manufacturers are also improving software and hardware interfaces to make systems easier for clinical teams to operate. Continued innovation in surgical monitoring is therefore creating opportunities for neurology device companies while supporting safer and more efficient procedural environments.

In May 2026, Washington-based Cadwell Industries announced the U.S. commercial launch of Cadwell Guardian™, a next-generation intraoperative neuromonitoring platform with pod-based architecture, advanced recording and stimulation capabilities, and workflow features for surgical environments.

Critical Challenges Facing the United States Neurology Devices Industry

1. Complex Regulatory and Clinical Validation Requirements

Neurology devices often involve sophisticated technologies that interact directly or indirectly with the nervous system, making clinical validation particularly demanding. Manufacturers must demonstrate appropriate safety, performance, reliability, and clinical usefulness before expanding commercial applications. Devices involving brain stimulation, implanted components, neural interfaces, or novel therapeutic mechanisms may require extensive clinical investigation and careful regulatory engagement. Developers must also demonstrate that software, hardware, stimulation parameters, and monitoring functions perform consistently across different patient populations and clinical settings. These requirements can lengthen development timelines and increase costs. Smaller neurotechnology companies may face additional challenges when building clinical evidence, navigating regulatory pathways, and establishing commercial infrastructure alongside larger established medical-device manufacturers.

2. High Technical Complexity and Clinical Adoption Barriers

Advanced neurological devices frequently combine sophisticated hardware, software, sensors, stimulation technologies, and data-processing capabilities. Integrating these components while maintaining reliability and ease of use can be technically challenging. Hospitals and clinicians may also require specialized training before adopting new technologies, particularly when devices alter established treatment workflows. For implanted or complex systems, patient selection, procedure requirements, follow-up, maintenance, and long-term monitoring can further influence adoption. Reimbursement considerations may also affect accessibility when innovative technologies fall outside conventional treatment pathways. Consequently, successful commercialization requires more than technological innovation; manufacturers must demonstrate practical clinical value, develop intuitive systems, provide appropriate training, and establish sustainable pathways for patient access.

California – Where Neurotechnology Meets Precision Medicine

California remains a highly innovative environment for neurology device development, supported by biotechnology companies, medical centers, universities, and technology-focused startups. The state's ecosystem encourages convergence between neuroscience, artificial intelligence, digital health, robotics, and medical-device engineering. Developers are working on wearable stimulation, neurorehabilitation, brain-computer interfaces, neurological monitoring, and personalized treatment systems. The combination of strong research capabilities and technology entrepreneurship supports rapid experimentation with new neurological applications. California is also becoming an important environment for commercialization because emerging companies can collaborate with healthcare providers and research institutions to evaluate novel devices in clinical settings. Continued convergence between software and medical-device engineering is expected to create new opportunities across diagnosis, monitoring, rehabilitation, and neuromodulation.

In June 2026, Valencia, California-based Bioness Medical announced FDA 510(k) clearance for its PoNS® Portable Neuromodulation Stimulator for dynamic gait deficit associated with chronic stroke symptoms, expanding its neurological rehabilitation application.

Texas – A Growing Hub for Neural Interfaces

Texas is developing a diverse neurological-device ecosystem spanning neurostimulation, neural interfaces, rehabilitation, surgical technologies, and brain-computer interfaces. Research institutions and technology companies are exploring ways to connect neural signals with external devices and develop less invasive approaches to neurological treatment. Austin and other major Texas healthcare and technology centers provide an environment for collaboration between engineers, neuroscientists, clinicians, and device developers. Neural-interface research is particularly promising for mobility assistance and communication technologies. Meanwhile, advances in stimulation and rehabilitation devices are broadening clinical applications. The state's combination of medical infrastructure and technology entrepreneurship provides favorable conditions for companies seeking to develop, test, and commercialize next-generation neurological technologies.

In March 2025, Austin-based Phantom Neuro announced FDA Breakthrough Device and Targeted Acceleration Pathway designations for its minimally invasive Phantom X neural interface platform, designed to support advanced human-machine interfaces and prosthetic control.

New York – Turning Brain Function into Actionable Insight

New York offers an important environment for neurological device innovation through its concentration of hospitals, universities, neuroscience researchers, and medical technology organizations. The state is supporting development in brain imaging, neurological assessment, neuromodulation, and digital monitoring. Greater interest in objective measurement of brain function is encouraging developers to create technologies that can complement conventional neurological examinations. Such devices may assist clinicians in evaluating neurological health, tracking disease progression, or assessing responses to interventions. The presence of major academic medical centers also facilitates clinical research and technology validation. As precision medicine becomes increasingly important, New York's research ecosystem can support the development of neurological devices that provide clinicians with more structured and actionable information.

In November 2025, New York-based QuantalX Neuroscience announced FDA De Novo classification for its Delphi-MD™ functional neuro-imaging system, enabling clinical use of the technology for neurological health and brain-function assessment.

Florida – Bringing Neuromodulation Closer to the Patient

Florida is emerging as an attractive market for neurology devices as healthcare providers increasingly adopt non-invasive and home-oriented neurological technologies. The state supports applications ranging from brain stimulation and neuromodulation to rehabilitation and neurological monitoring. Providers are increasingly interested in systems that can simplify treatment delivery while expanding access beyond highly specialized hospital environments. This is particularly relevant for chronic neurological and neuropsychiatric conditions requiring repeated intervention. The development of connected and portable systems can also support continuity between clinical consultations and ongoing treatment. Florida's growing healthcare infrastructure, specialized providers, and interest in innovative treatment models create opportunities for manufacturers introducing patient-friendly neurological technologies.

June 2026, ZETA SURGICAL and HOPE Therapeutics announced the first patient treatment using the FDA-cleared Zeta TMS Navigation System at a Sarasota, Florida clinic, followed by treatment deployment at West Palm Beach locations.

United States Neurostimulation Market

The United States neurostimulation market is evolving as healthcare providers increasingly adopt electrical and magnetic stimulation technologies for neurological and chronic conditions. Neurostimulation devices are being used across applications such as movement disorders, epilepsy, chronic pain, spinal disorders, tremor, and neurorehabilitation. Technological progress is supporting the development of minimally invasive, wearable, rechargeable, and programmable systems that can provide more personalized treatment. Closed-loop stimulation and improved sensing capabilities are also helping manufacturers develop devices that can respond to individual physiological signals. Growing interest in non-drug treatment options is encouraging continued innovation, while collaborations between medical-device companies, neurologists, researchers, and hospitals are supporting clinical development. The market is therefore moving toward more precise, patient-centered, and connected neurostimulation solutions.

United States Hospitals Neurology Devices Market

The United States hospitals neurology devices market is supported by the increasing adoption of advanced technologies for neurological diagnosis, intervention, monitoring, and rehabilitation. Hospitals utilize a broad range of devices, including neurostimulation systems, electroencephalography equipment, intraoperative neuromonitoring platforms, brain imaging technologies, surgical navigation systems, and neurological rehabilitation equipment. Growing demand for specialized neurological care is encouraging hospitals to modernize their diagnostic and therapeutic infrastructure. Advances in minimally invasive procedures and digitally connected devices are also improving clinical workflows and enabling more individualized treatment. Hospitals increasingly seek technologies that can integrate with existing information systems while providing reliable clinical data. Collaboration between medical-device manufacturers and healthcare institutions further supports technology evaluation, clinical training, and adoption of innovative neurological solutions across hospital settings.

Research Methodology of the United States Neurology Devices Market

The United States Neurology Devices Market was estimated using a structured bottom-up and top-down market-sizing methodology, supported by secondary research, device-level sales analysis, procedure-volume assessment, pricing analysis, company-level revenue estimation, regulatory evaluation, and data triangulation. The methodology considered medical devices used for diagnosing, monitoring, and treating neurological disorders, including devices for neurostimulation, neurosurgery, cerebrospinal fluid management, electroencephalography (EEG), and other neurological applications. The assessment focused on the United States and evaluated demand across hospitals, specialty clinics, ambulatory surgical centers, diagnostic centers, and other healthcare facilities.

1. Market Definition and Scope

• The market was first defined by establishing the scope of medical devices used for the diagnosis, monitoring, and treatment of neurological disorders.
• The assessment covered neurological devices used in conditions such as epilepsy, Parkinson's disease, Alzheimer's disease, stroke, chronic pain, traumatic brain injury, and other neurological disorders.
• The scope was limited to relevant neurological medical devices sold or used in the United States, with clear distinctions between devices, consumables, accessories, and related services to prevent double counting.

2. Secondary Research and Data Collection

• Secondary research was conducted to collect information on the United States neurology devices industry from reliable public and commercial sources.
• Data was gathered from the U.S. Food and Drug Administration (FDA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Centers for Medicare & Medicaid Services (CMS), National Institute of Neurological Disorders and Stroke (NINDS), and other relevant government agencies.
• FDA databases were reviewed for device approvals, clearances, product classifications, regulatory submissions, and manufacturer information.
• Company annual reports, investor presentations, product catalogs, financial statements, and official press releases were analyzed to identify device sales, product launches, technological developments, and commercial expansion.
• Clinical publications, hospital procedure statistics, disease prevalence reports, and medical association publications were examined to understand neurological disease burden and device utilization.
• Information on device pricing, reimbursement, clinical adoption, and procurement was collected wherever publicly available.
• The collected data was organized by device category, application, end user, and manufacturer to establish a consistent market-sizing framework.

3. Identification of Key Market Participants

• Companies involved in the development, manufacturing, and commercialization of neurological medical devices in the United States were identified.
• The analysis covered manufacturers of deep brain stimulation systems, vagus nerve stimulation devices, spinal cord stimulation systems, EEG equipment, neurosurgical instruments, and cerebrospinal fluid management products.
• Company portfolios were examined to identify relevant devices, product indications, distribution channels, regulatory status, and target healthcare facilities.
• Financial disclosures were reviewed to identify revenues generated from neurology devices and associated product categories.
• For diversified medical technology companies, neurology-related revenue was separated from revenues generated by unrelated medical devices and services.
• Where companies did not disclose neurology-specific revenue, estimates were developed using product portfolios, reported segment revenues, device sales information, and other relevant secondary sources.
• Company-level estimates were consolidated while accounting for overlapping product portfolios and potential double counting.

4. Device-Level Product and Technology Analysis

• Neurological devices were classified according to their clinical purpose, operating technology, implantation requirements, and therapeutic or diagnostic application.
• Neurostimulation devices were evaluated by examining deep brain stimulation, vagus nerve stimulation, responsive neurostimulation, and other relevant stimulation technologies.
• Neurological diagnostic and monitoring devices were assessed through EEG systems, intracranial pressure monitors, and other equipment used to evaluate neurological function.
• Neurosurgical devices were examined based on their use in brain and spinal procedures, including instruments and equipment designed for neurological interventions.
• Cerebrospinal fluid management devices were assessed through shunts, drainage systems, and related products used to manage conditions such as hydrocephalus.
• Product-level information was collected on device availability, regulatory clearances, clinical indications, technology features, and commercial adoption.
• Differences between implantable and non-invasive devices, capital equipment and disposable products, and therapeutic and diagnostic devices were considered when calculating market revenue.

5. Disease Burden and Procedure-Volume Analysis

• The demand for neurology devices was evaluated by examining the prevalence and incidence of neurological disorders and the procedures associated with their diagnosis and treatment.
• Data from the CDC, NIH, NINDS, clinical publications, and other relevant sources was reviewed to establish the number of patients affected by major neurological conditions in the United States.
• Relevant populations were assessed for conditions such as Parkinson's disease, epilepsy, stroke, chronic pain, traumatic brain injury, and hydrocephalus.
• The analysis considered the proportion of patients who required device-based diagnosis, monitoring, surgical intervention, or neuromodulation therapy.
• Procedure volumes for relevant neurological interventions were examined using hospital statistics, clinical literature, and publicly available healthcare utilization data.
• Disease prevalence was not directly treated as device demand; instead, the assessment accounted for diagnosis rates, clinical eligibility, treatment adoption, procedure frequency, and device utilization.
• The resulting patient and procedure estimates were used to validate device sales volumes and assess the relative contribution of each application.

• Formulas used:

• Eligible Patient Population = Total Relevant Patient Population × Percentage Clinically Eligible for Device-Based Treatment
• Estimated Annual Procedures = Eligible Patient Population × Annual Procedure Rate
• Estimated Devices Required = Annual Procedures × Average Number of Devices Used per Procedure
• Estimated Annual Device Demand = New Device Implantations + Replacement Devices + Other Applicable Device Units

6. Market Estimation Using the Bottom-Up Approach

• The bottom-up approach was used to estimate the United States neurology devices market by aggregating revenues from individual device categories, manufacturers, and relevant product lines.
• Available sales volumes, device shipments, product-level revenues, average selling prices, and relevant company disclosures were examined.
• For devices with identifiable unit sales, annual revenue was calculated using estimated sales volumes and average selling prices.
• For implantable devices, demand was assessed using annual procedure volumes, new implantations, replacement requirements, and the average number of devices used per procedure.
• For diagnostic and monitoring equipment, estimates were developed using the number of healthcare facilities, equipment installations, replacement cycles, and average equipment prices.
• For disposable and recurring-use products, annual consumption volumes and average selling prices were used to estimate revenue.
• Where product-specific sales figures were unavailable, estimates were developed using company disclosures, procedure statistics, installed-base information, and comparable product data.

• Formulas used:

• Device-Level Revenue = Number of Devices Sold × Average Selling Price per Device
• Implantable Device Revenue = Annual Implantations × Average Selling Price per Device
• Diagnostic Equipment Revenue = Units Sold × Average Selling Price per Equipment Unit
• Consumables Revenue = Annual Units Consumed × Average Selling Price per Unit
• Company-Level Neurology Device Revenue = Sum of Relevant Neurology Device Product Revenues
• Bottom-Up Market Size = Sum of Revenues Across All Relevant Neurology Device Categories

7. Market Estimation Using the Top-Down Approach

• The top-down approach was used to validate the market estimate by reviewing broader medical device markets and identifying the revenue attributable to neurological devices.
• Relevant company financial statements, medical technology segment disclosures, device market information, and healthcare expenditure data were examined.
• The share of revenue attributable to neurology devices was estimated for companies reporting combined revenues from multiple medical technology categories.
• The analysis considered the contribution of neurostimulation, neurosurgical devices, cerebrospinal fluid management systems, and neurological diagnostic and monitoring equipment.
• Revenue from unrelated medical devices, pharmaceutical products, and non-device healthcare services was excluded.
• Geographic adjustments were applied to account for United States sales rather than global revenue.
• The resulting estimate was compared with the bottom-up calculation to identify inconsistencies in device coverage, company revenue allocation, and market segmentation.

• Formulas used:

• Neurology Device Revenue = Relevant Medical Device Revenue × Estimated Neurology Device Contribution Percentage
• United States Neurology Device Revenue = Relevant Global Neurology Device Revenue × Estimated United States Revenue Share
• Top-Down Market Size = Sum of Estimated United States Revenues Across Neurology Device Categories

8. Pricing and Revenue Analysis

• Pricing analysis was conducted to estimate the average selling prices of neurological medical devices across therapeutic, diagnostic, monitoring, and surgical categories.
• Pricing information was collected from manufacturer product catalogs, publicly available procurement records, hospital purchasing information, company disclosures, and other reliable secondary sources.
• Differences in prices were assessed according to device type, technological complexity, clinical application, implantation requirements, and product specifications.
• Implantable devices were evaluated separately from non-invasive equipment because of differences in product costs, implantation requirements, and replacement cycles.
• Diagnostic equipment prices were assessed based on system configuration, monitoring capabilities, software integration, and associated accessories.
• Disposable products and recurring-use components were evaluated using annual consumption volumes and applicable unit prices.
• Where direct transaction prices were unavailable, average selling prices were estimated using comparable products, disclosed financial information, and available pricing benchmarks.
• Reimbursement information was reviewed where relevant to understand the economic factors influencing device adoption, without treating reimbursement payments as equivalent to manufacturer revenue.

• Formulas used:

• Average Selling Price (ASP) = Total Device Revenue ÷ Number of Devices Sold
• Estimated Device Revenue = Units Sold × Average Selling Price
• Annual Consumables Revenue = Units Consumed × Average Selling Price per Unit
• Weighted Average Selling Price = Total Revenue Across Relevant Products ÷ Total Units Sold Across Those Products

9. Regulatory Approval and Clinical Adoption Analysis

• The regulatory environment for neurology devices in the United States was assessed using FDA databases and official regulatory publications.
• Relevant devices were reviewed according to their regulatory pathways, including 510(k) clearances, premarket approvals (PMAs), and applicable investigational device requirements.
• FDA product records were used to identify commercially available devices, approved indications, manufacturers, and significant regulatory milestones.
• Clinical adoption was evaluated using scientific publications, clinical guidelines, hospital utilization information, and documented treatment practices.
• Newly cleared devices and technological innovations were examined to determine their potential influence on market adoption and product replacement.
• The analysis distinguished commercially available devices from investigational technologies that had not yet achieved the relevant authorization for routine commercial use.
• Regulatory developments and clinical evidence were incorporated into the market forecast where they were expected to affect product availability, treatment eligibility, and demand.

10. End-User and Distribution Channel Analysis

• Demand was evaluated across hospitals, specialty neurology clinics, ambulatory surgical centers, diagnostic centers, and other healthcare facilities.
• Hospitals were assessed based on their neurological surgery capabilities, patient volumes, equipment installations, and use of advanced neuromodulation and monitoring systems.
• Specialty clinics were evaluated based on their diagnosis and treatment of neurological disorders and their use of diagnostic, monitoring, and selected therapeutic devices.
• Ambulatory surgical centers were assessed for their contribution to eligible neurological procedures performed outside traditional hospital settings.
• Diagnostic centers and other facilities were evaluated according to their use of EEG equipment and other neurological testing systems.
• Distribution channels were examined through direct manufacturer sales, medical device distributors, hospital procurement arrangements, and other relevant purchasing routes.
• Revenue was allocated by end user and distribution channel while avoiding double counting of manufacturer sales and distributor resale values.

11. Historical Market Analysis and Forecasting

• Historical market performance was assessed using device sales disclosures, regulatory clearances, product launches, neurological procedure volumes, and changes in clinical adoption.
• Demand trends were evaluated in relation to the prevalence of neurological disorders, the aging population, advances in neurostimulation, and improvements in diagnostic and surgical technologies.
• Forecast assumptions were developed by assessing expected device adoption, replacement demand, procedure volumes, pricing changes, and the commercialization of new products.
• The potential expansion of minimally invasive procedures, implantable neuromodulation technologies, and advanced neurological monitoring systems was considered.
• Forecasts accounted for constraints such as device costs, reimbursement limitations, clinical eligibility, regulatory requirements, and the availability of specialized healthcare professionals.
• Different growth scenarios were evaluated where changes in clinical practice, technology adoption, or regulatory outcomes could materially affect market development.

• Formulas used:

• Market Growth Rate (%) = [(Current Year Market Size ÷ Previous Year Market Size) − 1] × 100
• Forecast Market Size = Base-Year Market Size × (1 + Annual Growth Rate)ⁿ
• CAGR (%) = [(Ending Market Size ÷ Beginning Market Size)^(1 ÷ n) − 1] × 100

12. Data Triangulation and Final Market Validation

• The bottom-up and top-down estimates were compared to identify discrepancies in product coverage, company revenues, application allocation, and geographic scope.
• Device-level estimates were cross-checked against manufacturer disclosures, procedure volumes, installed-base information, regulatory records, and available pricing benchmarks.
• Company revenues from unrelated medical technology products were excluded to maintain the accuracy of the neurology devices market estimate.
• Potential double counting between capital equipment, disposable products, accessories, and related services was reviewed and adjusted.
• Patient-based demand estimates were compared with observed device utilization and procedure volumes to validate assumptions about clinical eligibility and adoption.
• Historical trends, regulatory developments, clinical adoption patterns, and product launches were reviewed to ensure that market projections remained consistent with the available evidence.
• Estimates based on limited public disclosures were assessed using comparable product information and other reliable secondary sources.
• The final United States neurology devices market size was established after reconciling the estimates and validating the assumptions across device categories, applications, end users, and manufacturers.

Market Segmentations

Product

• Neurostimulation
• Neurosurgery Devices
• Interventional Neurology
• CSF Management Devices
• Others

End Use

• Hospitals
• Ambulatory Surgery Centers
• Others

States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All Key Players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Medtronic Plc.
• B. Braun Melsungen AG 
• Boston Scientific Corporation 
• Stryker Corporation
• Abbott Laboratories
• Johnson and Johnson
• Smith & Nephew
• MicroPort Scientific Corporation

Report Details: